MoonLake Immunotherapeutics

Immunology (clinical-stage biotech)

MLTX · Nasdaq · Switzerland

Share price · MLTX

$10.79-5.55 (-33.97%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.3M (0.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when MLTX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 11 Nov 2026+7.6%
  2. 9 Nov 2026+9.5%

    Nothing announced by MLTX that day or the session before.

  3. 22 Oct 2026+15.9%
  4. 24 Sep 2026-6.0%

    Nothing announced by MLTX that day or the session before.

  5. 9 Sep 2026-8.2%
  6. 24 Jun 2026-5.7%
  7. 22 Jun 2026+15.4%
  8. 21 May 2026+8.3%

    Nothing announced by MLTX that day or the session before.

  9. 11 May 2026+10.4%
  10. 1 Apr 2026-11.4%

    Nothing announced by MLTX that day or the session before.

Share of unusual movement by asset

For each asset, the share of MLTX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
IL-17A/FAntibody-derived scaffold
Psoriatic ArthritisPsoriasisHidradenitis Suppurativa

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
January 2027 (1)
sonelokimabPhase 3Arthritis, Psoriatic
Est. primary completion 2027-01-04 · NCT06641089 · CT.gov ↗
What to watch
2028 (2)
February 2028 (1)
sonelokimabPhase 3Arthritis, Psoriatic
Est. primary completion 2028-02-04 · NCT07223138 · CT.gov ↗
What to watch
June 2028 (1)
sonelokimabPhase 3Hidradenitis Suppurativa
Est. primary completion 2028-06-13 · NCT07007637 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

10 August 2026Topline resultsonelokimabIZAR-1 Phase 3 (NCT06641076) met its primary endpoint (ACR50 at Week 16)
MoonLake Immunotherapeutics · Source ↗
September 2025Topline resultsonelokimabVELA-1 and VELA-2 Phase 3 Week 16 results: VELA-1 met its primary endpoint (HiSCR75); VELA-2 missed it on the composite strategy
MoonLake Immunotherapeutics · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$69M$383M+ $119M short-term inv.$80M-$63M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$50M$478M+ $59M short-term inv.$62M-$56M operating cash flowreport ↗
2026-Q1—$55M$298M+ $59M short-term inv.$70M-$66M operating cash flowreport ↗
2025-Q3—$61M$351M+ $30M short-term inv.$70M-$45M operating cash flowreport ↗
2025-Q2—$50M$307M+ $118M short-term inv.$55M-$55M operating cash flowreport ↗
2025-Q1—$36M$272M+ $209M short-term inv.$40M-$38M operating cash flowreport ↗
2024-Q3—$36M$376M+ $118M short-term inv.$35M-$25M operating cash flowreport ↗
2024-Q2—$24M$343M+ $177M short-term inv.$24M-$28M operating cash flowreport ↗
2024-Q1—$13M$458M+ $89M short-term inv.$14M-$15M operating cash flowreport ↗
2023-Q3—$7.6M$318M+ $178M short-term inv.$9.4M-$9.3M operating cash flowreport ↗
2023-Q2—$8.7M$502M+ $0 short-term inv.$10M-$12M operating cash flowreport ↗
2023-Q1—$7.4M$50M+ $13M short-term inv.$9.0M-$9.0M operating cash flowreport ↗
2022-Q3—$9.0M$41M+ $42M short-term inv.$10M-$9.3M operating cash flowreport ↗
2022-Q2—$11M$93M$12M-$34M operating cash flowreport ↗
2022-Q1—$10M$101M$2.7M-$0.8M operating cash flowreport ↗
2021-Q3—$0.7M$0.5M$2.1M-$0.1M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$203M$335M+ $59M short-term inv.$57M-$196M operating cash flowreport ↗

MoonLake did not disclose revenue. R&D spend was $202.86M, up 79.9% YoY from $112.77M, while cash and equivalents stood at $334.52M, with cash, equivalents and short-term marketable debt securities of $394.0M at year-end. The company reported a net loss of $227.32M and a quarterly net burn of $227.32M.

MoonLake announced positive topline results from the Phase 2 S-OLARIS trial of sonelokimab in axial spondyloarthritis, with 81% of patients achieving ASAS40 by Week 12 and similar improvements in ASDAS-CRP and SPARCC MRI scores. The company also amended its Hercules Capital debt facility with a concurrent $25M drawdown, leaving up to $400M in non-dilutive funds available, and expects cash plus proceeds from a $75M equity raise to fund operations into the second half of 2027. Upcoming milestones include 52-week VELA-1 and VELA-2 data in Q2 2026, IZAR-1 and VELA-TEEN readouts in mid-2026, and a planned H2 2026 BLA submission for hidradenitis suppurativa, alongside IZAR-2 results in H2 2026.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$113M$180M+ $268M short-term inv.$30M-$117M operating cash flowreport ↗
2023-FY—$32M$451M+ $60M short-term inv.$9.0M-$43M operating cash flowreport ↗
2022-FY—$42M$40M+ $33M short-term inv.$12M-$56M operating cash flowreport ↗
2021-FY——$8.0M+ $0 short-term inv.$1.1M-$0.6M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 27 sales ($83.0M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-07-27Reich Kristian · Chief Scientific OfficerOpen-market sale1,100$20.00$22KForm 4
2026-07-22Reich Kristian · Chief Scientific OfficerOpen-market sale2,448$20.00$49KForm 4
2026-07-21Reich Kristian · Chief Scientific OfficerOpen-market sale50,000$20.02$1.0MForm 4
2026-07-20Reich Kristian · Chief Scientific OfficerOpen-market sale43,700$20.09$878KForm 4
2026-07-15Reich Kristian · Chief Scientific OfficerOpen-market sale16,105$20.01$322KForm 4
2026-07-10Santos da Silva Jorge · director, Chief Executive OfficerOpen-market sale68,289$20.02$1.4MForm 4
2026-07-09Santos da Silva Jorge · director, Chief Executive OfficerOpen-market sale33,936$20.01$679KForm 4
2026-07-01Santos da Silva Jorge · director, Chief Executive OfficerOpen-market sale47,775$20.03$957KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 146 reporting institutions held 63.3M shares ($1.1B, 78.0% of shares outstanding).

#InstitutionSharesValue
1BVF INC/IL16,001,284$298.3M
2Deep Track Capital, LP6,408,863$119.5M
3Cormorant Asset Management, LP4,480,433$83.5M
4JANUS HENDERSON GROUP PLC3,451,628$64.3M
5D. E. Shaw & Co., Inc.2,390,661$44.6M
6MPM BIOIMPACT LLC1,811,082$33.8M
7Weiss Asset Management LP1,708,328$31.8M
8Logos Global Management LP1,500,000$28.0M
9Point72 Asset Management, L.P.1,368,518$25.5M
10CITADEL ADVISORS LLC1,323,728$24.7M
11GOLDMAN SACHS GROUP INC1,130,233$21.1M
12TWO SIGMA INVESTMENTS, LP1,122,312$20.9M
13Balyasny Asset Management L.P.1,065,610$19.9M
14BlackRock, Inc.1,021,851$19.0M
15Vivo Capital, LLC1,000,000$18.6M